An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival
Blood transfusions have the potential to improve graft survival, induce sensitization, and transmit infections. Current clinical practice is to minimize transfusions in renal transplantation candidates, but it is unclear if the evidence continues to support pre-transplant transfusion avoidance. Chan...
Gespeichert in:
| Veröffentlicht in: | BMC nephrology 2013-10, Vol.14 (1), p.217-217, Article 217 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 217 |
|---|---|
| container_issue | 1 |
| container_start_page | 217 |
| container_title | BMC nephrology |
| container_volume | 14 |
| creator | Scornik, Juan C Bromberg, Jonathan S Norman, Douglas J Bhanderi, Mayank Gitlin, Matthew Petersen, Jeffrey |
| description | Blood transfusions have the potential to improve graft survival, induce sensitization, and transmit infections. Current clinical practice is to minimize transfusions in renal transplantation candidates, but it is unclear if the evidence continues to support pre-transplant transfusion avoidance. Changes in the Medicare prospective payment system may increase transfusion rates. Thus there is a need to re-evaluate the literature to improve the management options for renal transplant candidates.
A review applying a systematic approach and conducted using MEDLINE(®), Embase(®), and the Cochrane Library for English-language publications (timeframe: 01/1984-03/2011) captured 180 studies and data from publically available registries and assessed the impact of transfusions on allosensitization and graft survival, and the impact of allosensitization on graft survival and wait time.
Blood transfusions continued to be a major cause of allosensitization, with allosensitization associated with increased rejection and graft loss, and longer wait times to transplantation. Although older studies showed a beneficial effect of transfusion on graft survival, this benefit has largely disappeared in the post-cyclosporine era due to improved graft outcomes with current practice. Recent data suggested that it may be the donor-specific antibody component of allosensitization that carried the risk to graft outcomes.
Results of this review indicated that avoiding transfusions whenever possible is a sound management option that could prevent detrimental effects in patients awaiting kidney transplantation. |
| doi_str_mv | 10.1186/1471-2369-14-217 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4125965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534607481</galeid><sourcerecordid>A534607481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c557t-d4ed9fcb0fbff98da44b0b29816f5be73249d821cc8d27f760430ddc211709283</originalsourceid><addsrcrecordid>eNptUk1v1DAQjRCIlsKdE7LEhUuKx3YS54K0qviSKnEpZ8vxx9ZVYgfbWQmO_eV1tu2yRcgHj2bee_OhV1VvAZ8D8PYjsA5qQtu-BlYT6J5Vp4fU86P4pHqV0g3G0HGGX1YnhAHucE9Pq9uNR8usZTYoeJSvDXLTLFVGwaI5mjpH6dM8Sp_RPrRLcsEnJL1GchxDMj657P7IXNJ7CTcZlAOKxssRHdFXRqmvpG2UNqO0xJ3byfF19cLKMZk3D_9Z9fPL56uLb_Xlj6_fLzaXtWqaLteaGd1bNWA7WNtzLRkb8EB6Dq1tBtNRwnrNCSjFNels12JGsdaKAJRVCadn1ad73XkZJqOV8WW6UczRTTL-FkE68bTi3bXYhp1gQJq-bYrAhweBGH4tJmUxuaTMWNYzYUkCWNNDmZVCgb7_B3oTllguskdxygEo_4vaytEI520ofdUqKjYNZS3uGF-1zv-DKk-byangjXUl_4SA7wkqhpSisYcdAYvVN2I1hliNUSJRfFMo745vcyA8GoXeAbMtv1A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1458381138</pqid></control><display><type>article</type><title>An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Scornik, Juan C ; Bromberg, Jonathan S ; Norman, Douglas J ; Bhanderi, Mayank ; Gitlin, Matthew ; Petersen, Jeffrey</creator><creatorcontrib>Scornik, Juan C ; Bromberg, Jonathan S ; Norman, Douglas J ; Bhanderi, Mayank ; Gitlin, Matthew ; Petersen, Jeffrey</creatorcontrib><description>Blood transfusions have the potential to improve graft survival, induce sensitization, and transmit infections. Current clinical practice is to minimize transfusions in renal transplantation candidates, but it is unclear if the evidence continues to support pre-transplant transfusion avoidance. Changes in the Medicare prospective payment system may increase transfusion rates. Thus there is a need to re-evaluate the literature to improve the management options for renal transplant candidates.
A review applying a systematic approach and conducted using MEDLINE(®), Embase(®), and the Cochrane Library for English-language publications (timeframe: 01/1984-03/2011) captured 180 studies and data from publically available registries and assessed the impact of transfusions on allosensitization and graft survival, and the impact of allosensitization on graft survival and wait time.
Blood transfusions continued to be a major cause of allosensitization, with allosensitization associated with increased rejection and graft loss, and longer wait times to transplantation. Although older studies showed a beneficial effect of transfusion on graft survival, this benefit has largely disappeared in the post-cyclosporine era due to improved graft outcomes with current practice. Recent data suggested that it may be the donor-specific antibody component of allosensitization that carried the risk to graft outcomes.
Results of this review indicated that avoiding transfusions whenever possible is a sound management option that could prevent detrimental effects in patients awaiting kidney transplantation.</description><identifier>ISSN: 1471-2369</identifier><identifier>EISSN: 1471-2369</identifier><identifier>DOI: 10.1186/1471-2369-14-217</identifier><identifier>PMID: 24107093</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Antibodies ; Biotechnology industry ; Blood transfusion ; Blood Transfusion - methods ; Blood Transfusion - statistics & numerical data ; Cytotoxicity ; Data analysis ; Disease transmission ; FDA approval ; Graft Survival ; Health aspects ; Humans ; Immunization - methods ; Kidney diseases ; Kidney Transplantation - methods ; Kidney Transplantation - statistics & numerical data ; Kidneys ; Mortality ; Nephrology ; Objectives ; Patient outcomes ; Preoperative Care - methods ; Preoperative Care - statistics & numerical data ; Prospective payment systems ; Risk Factors ; Studies ; Transplantation ; Transplants & implants ; Treatment Outcome ; Viral antibodies ; Waiting Lists</subject><ispartof>BMC nephrology, 2013-10, Vol.14 (1), p.217-217, Article 217</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Scornik et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Scornik et al.; licensee BioMed Central Ltd. 2013 Scornik et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c557t-d4ed9fcb0fbff98da44b0b29816f5be73249d821cc8d27f760430ddc211709283</citedby><cites>FETCH-LOGICAL-c557t-d4ed9fcb0fbff98da44b0b29816f5be73249d821cc8d27f760430ddc211709283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125965/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125965/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24107093$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scornik, Juan C</creatorcontrib><creatorcontrib>Bromberg, Jonathan S</creatorcontrib><creatorcontrib>Norman, Douglas J</creatorcontrib><creatorcontrib>Bhanderi, Mayank</creatorcontrib><creatorcontrib>Gitlin, Matthew</creatorcontrib><creatorcontrib>Petersen, Jeffrey</creatorcontrib><title>An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival</title><title>BMC nephrology</title><addtitle>BMC Nephrol</addtitle><description>Blood transfusions have the potential to improve graft survival, induce sensitization, and transmit infections. Current clinical practice is to minimize transfusions in renal transplantation candidates, but it is unclear if the evidence continues to support pre-transplant transfusion avoidance. Changes in the Medicare prospective payment system may increase transfusion rates. Thus there is a need to re-evaluate the literature to improve the management options for renal transplant candidates.
A review applying a systematic approach and conducted using MEDLINE(®), Embase(®), and the Cochrane Library for English-language publications (timeframe: 01/1984-03/2011) captured 180 studies and data from publically available registries and assessed the impact of transfusions on allosensitization and graft survival, and the impact of allosensitization on graft survival and wait time.
Blood transfusions continued to be a major cause of allosensitization, with allosensitization associated with increased rejection and graft loss, and longer wait times to transplantation. Although older studies showed a beneficial effect of transfusion on graft survival, this benefit has largely disappeared in the post-cyclosporine era due to improved graft outcomes with current practice. Recent data suggested that it may be the donor-specific antibody component of allosensitization that carried the risk to graft outcomes.
Results of this review indicated that avoiding transfusions whenever possible is a sound management option that could prevent detrimental effects in patients awaiting kidney transplantation.</description><subject>Analysis</subject><subject>Antibodies</subject><subject>Biotechnology industry</subject><subject>Blood transfusion</subject><subject>Blood Transfusion - methods</subject><subject>Blood Transfusion - statistics & numerical data</subject><subject>Cytotoxicity</subject><subject>Data analysis</subject><subject>Disease transmission</subject><subject>FDA approval</subject><subject>Graft Survival</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunization - methods</subject><subject>Kidney diseases</subject><subject>Kidney Transplantation - methods</subject><subject>Kidney Transplantation - statistics & numerical data</subject><subject>Kidneys</subject><subject>Mortality</subject><subject>Nephrology</subject><subject>Objectives</subject><subject>Patient outcomes</subject><subject>Preoperative Care - methods</subject><subject>Preoperative Care - statistics & numerical data</subject><subject>Prospective payment systems</subject><subject>Risk Factors</subject><subject>Studies</subject><subject>Transplantation</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><subject>Viral antibodies</subject><subject>Waiting Lists</subject><issn>1471-2369</issn><issn>1471-2369</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptUk1v1DAQjRCIlsKdE7LEhUuKx3YS54K0qviSKnEpZ8vxx9ZVYgfbWQmO_eV1tu2yRcgHj2bee_OhV1VvAZ8D8PYjsA5qQtu-BlYT6J5Vp4fU86P4pHqV0g3G0HGGX1YnhAHucE9Pq9uNR8usZTYoeJSvDXLTLFVGwaI5mjpH6dM8Sp_RPrRLcsEnJL1GchxDMj657P7IXNJ7CTcZlAOKxssRHdFXRqmvpG2UNqO0xJ3byfF19cLKMZk3D_9Z9fPL56uLb_Xlj6_fLzaXtWqaLteaGd1bNWA7WNtzLRkb8EB6Dq1tBtNRwnrNCSjFNels12JGsdaKAJRVCadn1ad73XkZJqOV8WW6UczRTTL-FkE68bTi3bXYhp1gQJq-bYrAhweBGH4tJmUxuaTMWNYzYUkCWNNDmZVCgb7_B3oTllguskdxygEo_4vaytEI520ofdUqKjYNZS3uGF-1zv-DKk-byangjXUl_4SA7wkqhpSisYcdAYvVN2I1hliNUSJRfFMo745vcyA8GoXeAbMtv1A</recordid><startdate>20131010</startdate><enddate>20131010</enddate><creator>Scornik, Juan C</creator><creator>Bromberg, Jonathan S</creator><creator>Norman, Douglas J</creator><creator>Bhanderi, Mayank</creator><creator>Gitlin, Matthew</creator><creator>Petersen, Jeffrey</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20131010</creationdate><title>An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival</title><author>Scornik, Juan C ; Bromberg, Jonathan S ; Norman, Douglas J ; Bhanderi, Mayank ; Gitlin, Matthew ; Petersen, Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c557t-d4ed9fcb0fbff98da44b0b29816f5be73249d821cc8d27f760430ddc211709283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Analysis</topic><topic>Antibodies</topic><topic>Biotechnology industry</topic><topic>Blood transfusion</topic><topic>Blood Transfusion - methods</topic><topic>Blood Transfusion - statistics & numerical data</topic><topic>Cytotoxicity</topic><topic>Data analysis</topic><topic>Disease transmission</topic><topic>FDA approval</topic><topic>Graft Survival</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunization - methods</topic><topic>Kidney diseases</topic><topic>Kidney Transplantation - methods</topic><topic>Kidney Transplantation - statistics & numerical data</topic><topic>Kidneys</topic><topic>Mortality</topic><topic>Nephrology</topic><topic>Objectives</topic><topic>Patient outcomes</topic><topic>Preoperative Care - methods</topic><topic>Preoperative Care - statistics & numerical data</topic><topic>Prospective payment systems</topic><topic>Risk Factors</topic><topic>Studies</topic><topic>Transplantation</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><topic>Viral antibodies</topic><topic>Waiting Lists</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scornik, Juan C</creatorcontrib><creatorcontrib>Bromberg, Jonathan S</creatorcontrib><creatorcontrib>Norman, Douglas J</creatorcontrib><creatorcontrib>Bhanderi, Mayank</creatorcontrib><creatorcontrib>Gitlin, Matthew</creatorcontrib><creatorcontrib>Petersen, Jeffrey</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scornik, Juan C</au><au>Bromberg, Jonathan S</au><au>Norman, Douglas J</au><au>Bhanderi, Mayank</au><au>Gitlin, Matthew</au><au>Petersen, Jeffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival</atitle><jtitle>BMC nephrology</jtitle><addtitle>BMC Nephrol</addtitle><date>2013-10-10</date><risdate>2013</risdate><volume>14</volume><issue>1</issue><spage>217</spage><epage>217</epage><pages>217-217</pages><artnum>217</artnum><issn>1471-2369</issn><eissn>1471-2369</eissn><abstract>Blood transfusions have the potential to improve graft survival, induce sensitization, and transmit infections. Current clinical practice is to minimize transfusions in renal transplantation candidates, but it is unclear if the evidence continues to support pre-transplant transfusion avoidance. Changes in the Medicare prospective payment system may increase transfusion rates. Thus there is a need to re-evaluate the literature to improve the management options for renal transplant candidates.
A review applying a systematic approach and conducted using MEDLINE(®), Embase(®), and the Cochrane Library for English-language publications (timeframe: 01/1984-03/2011) captured 180 studies and data from publically available registries and assessed the impact of transfusions on allosensitization and graft survival, and the impact of allosensitization on graft survival and wait time.
Blood transfusions continued to be a major cause of allosensitization, with allosensitization associated with increased rejection and graft loss, and longer wait times to transplantation. Although older studies showed a beneficial effect of transfusion on graft survival, this benefit has largely disappeared in the post-cyclosporine era due to improved graft outcomes with current practice. Recent data suggested that it may be the donor-specific antibody component of allosensitization that carried the risk to graft outcomes.
Results of this review indicated that avoiding transfusions whenever possible is a sound management option that could prevent detrimental effects in patients awaiting kidney transplantation.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>24107093</pmid><doi>10.1186/1471-2369-14-217</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2369 |
| ispartof | BMC nephrology, 2013-10, Vol.14 (1), p.217-217, Article 217 |
| issn | 1471-2369 1471-2369 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4125965 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Analysis Antibodies Biotechnology industry Blood transfusion Blood Transfusion - methods Blood Transfusion - statistics & numerical data Cytotoxicity Data analysis Disease transmission FDA approval Graft Survival Health aspects Humans Immunization - methods Kidney diseases Kidney Transplantation - methods Kidney Transplantation - statistics & numerical data Kidneys Mortality Nephrology Objectives Patient outcomes Preoperative Care - methods Preoperative Care - statistics & numerical data Prospective payment systems Risk Factors Studies Transplantation Transplants & implants Treatment Outcome Viral antibodies Waiting Lists |
| title | An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T10%3A15%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20update%20on%20the%20impact%20of%20pre-transplant%20transfusions%20and%20allosensitization%20on%20time%20to%20renal%20transplant%20and%20on%20allograft%20survival&rft.jtitle=BMC%20nephrology&rft.au=Scornik,%20Juan%20C&rft.date=2013-10-10&rft.volume=14&rft.issue=1&rft.spage=217&rft.epage=217&rft.pages=217-217&rft.artnum=217&rft.issn=1471-2369&rft.eissn=1471-2369&rft_id=info:doi/10.1186/1471-2369-14-217&rft_dat=%3Cgale_pubme%3EA534607481%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1458381138&rft_id=info:pmid/24107093&rft_galeid=A534607481&rfr_iscdi=true |